Evidence for immune facilitation of breast cancer growth and for the immune promotion of oncogenesis in breast cancer

Medicina

Volumn 56, Issue SUPPL. 1, 1996, Pages 13-24

  Stewart, Thomas H M ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; BREAST TUMOR; CELL DIVISION; CELL TRANSFORMATION; FEMALE; HUMAN; IMMUNOLOGY; METABOLISM; MOUSE; PATHOLOGY; REVIEW;

ANIMALS; BREAST NEOPLASMS; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; MICE;

EID: 0030320432     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (96)

1. Stewart THM, Raman S. Adjuvant treatment of non-small cell lung cancer: a meta-analysis. In: Stewart THM, Wheelock EF (eds). Cellular immune mechanisms and tumor dormancy, Boca Raton: CRC Press 1992 213-28.
2. McKenzie JM, Zakarija M. Assays of the thyroid-stimulating antibodies (TSAb) of Grave's disease. In Ingbar SH, Braverman LE (eds). Werner's The thyroid, a fundamental and clinical text. Fifth edition. Philadelphia: JP Lippincott Company 1986; 559-75.
3. Volpé R. Pathogenesis of autoimmune thyroid disease. Ibid. 1986, 746-67.
4. Waksman BH. Experimental allergic encephalomyelitis and the «auto allergic» diseases. Int Arch All Suppl. 1959; 14: 1-87.
5. Waksman BH. Autoimmunization and the lesions of autoimmunity. Medicine (Bait) 1962; 41: 93-141.
6. Brent L, Brown J, Medawar PB. Skin transplantation immunity in relation to hypersensitivity. Lancet 1958; 34: 561-3.
7. Hughes LE, Lytton B. Antigenic properties of human tumors: delayed cutaneous hypersensitivity reactions. Br Med J: 1964; 209-12.
8. Stewart THM. The presence of delayed hypersensitivity reactions in patients toward cellular extracts of their own tumors. 1. The role of tissue antigen, nonspecific reactions of nuclear material, and bacterial antigen as a cause for this phenomenon. Cancer 1969; 23: 1368-79.
9. Stewart THM. The presence of delayed hypersen- sitivity reactions in patients toward celluiar extracts of their own tumors. 2. A correlation between the histologic picture of lymphocytic infiltrate of the tumor stroma, the presence of such a reaction, and a discussion of the significance of this phenomenon. Cancer 1969; 23: 1380-87.
10. Elston CW. Cellular reaction to choriocarcinoma. J Path 97: 261-68, 1969; 97: 261-68.
11. Elston CW. Cellular reaction to choriocarcinoma. J Path 97: 261-68, 1969; 97: 261-68.
12. Martin LJS, Woodruff MW, Webster JH, Picken JW. Testicular seminoma. A review of 179 patients treated over a 50 year period. Arch Surg 1965; 90: 306-12.
13. Murray D, Hreno A, Dutton J, Hampson LG. Prognosis in colon cancer, a pathologic reassess-ment. Cancer 196; 20:1976-85.
14. Spratt JS, Spjut HS. Prevalence and prognosis of individual and pathologic variables associated with colorectal carcinoma. Cancer 1967; 20:1976-85.
15. DiPaola M, Bertolotti A, Colizza S, Coli M. Histology of bronchial carcinoma and regional lymph nodes as putative immune response of the host to the tumor. J of Thoracic and Cardiovascular Surgery 1977; 73: 531-537.
16. Yesner R. A pathologist's view of tumor dormancy. In: Cellular immune mechanisms and tumor dormancy. Stewart THM, Wheelock EF (eds). Boca Raton: CRC Press 1992; 17-25.
17. Bloom HJG, Richardson WW, Field JR. Host resistance and survival in carcinoma of the breast: a study of 104 cases of medullary carcinoma in a series of 1,411 cases of breast cancer followed for 20 years. Br Med J 1970; 3: 181-8.
18. Mancim RE, Anchada JA, Saraceni AE, Bachman JC, Lavieri JC, Remirousky MJ. Immunological and testicular response in man sensitized with human testicular homogenate. J Clin Endocrinol Metab 1965; 25: 859-75.
19. Stewart THM, Orizaga M. The presence of delayed hypersensitivity reactions in patients toward cellular extracts of their malignant tumors. 3. The frequency, duration and cross reactivity of this phenomenon in patients with breast cancer and its correlation with survival. Cancer 1971; 28: 1472-1478.
20. Black MM. Personal communication.
21. Hollinshead AC, Stewart THM, Herberman RB. Delayed hypersensitivity reactions to soluble membrane antigens of human malignant lung cells. J Natl Cancer Inst 1974; 51: 1603-7.
22. Stewart THM, Hollinshead AC, Harris JE, et al. Specific active immunochemotherapy in lung cancer: a survival study. Can J Surg; 1977; 20: 3 70-377.
23. Takrta H, Hollinshead A, Hart J, et al. Adjuvant specific immunotherapy of resectable squamous cell lung carcinoma. Analysis at the eighth year. Cancer Immunol Immunother 1985; 20: 231-235.
24. Stewart THM, Shelley WE, Willan AR, Hollinshead A. An evaluation of the role of tumor-specific antigens. In: Annual Clinical Conference on Cancer. Lung cancer: current status and prospects for the future. The University of Texas System Cancer Center 1986; 28: 351-374.
25. Stewart THM, Raman S, Eidus L, et al. Two patients with non regional metastases of adenocarcinoma of the lung 11 and 14 years following surgery. Lung Cancer 1990; 6:28-40.
26. Stewart THM, Hollinshead AC, Raman S. Tumor dormancy: initiation, maintenance and termination in animals and humans. Can J Surg 1991; 34: 321-325.
27. Cellular Immune Mechanisms and Tumor Dormancy. Stewart THM, Wheelock EF (eds). Boca Raton: CRC Press, 1992.
28. Stewart THM, Raman S. Adjuvant treatment of non-smal-cell lung cancer: a meta-analysis. in Ibid 1992; 213-38.
29. Non-small-cell Lung Cancer Collaborative Group. Chemotherapy in non-small-cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995; 311: 899-909.
30. Raman S, Stewart THM. Meta analysis of clinical trials of specific immunotherapy of non-small-cell lung cancer, in Ibid 1992; 333-47.
31. Early Breast Cancer Trialists Collaborative Group. Systemic treatment of earty breast cancer by hormonal, cytotoxic or immune therapy. Lancet 71-85, 1992.
32. Wolf J, Spear P., Yesner R., Patno ME. The sex hormones and cortisone in the treatment of inoperable bronchogenic carcinoma. In Pincus G, Vollmer EP eds. Biological activities of steroids in relation to cancer. New York; Academic Press 1960; 413-26.
33. Stewart THM, Retsky MW, Tsai SCJ, Verma S. Dose response in the treatment of breast cancer. Lancet 1994; 343: 403-4.
34. Prehn RT, Lappé MA. An immunostimulation theory of tumor development. Transplant Rev 1971; 1: 26-54.
35. Prehn RT. Immunostimulation of the lymphodependent phase of neoplastic growth. J Natl Cancer Inst 1977; 59: 1043-9.
36. Prehn RT. Immunotherapy by chemotherapy. INSERM 1980; 97: 297-303.
37. Prehn RT, Prehn LM. The autoimmune nature of cancer. Cancer Res 1987; 47: 927-32.
38. Prehn RT. Stimulatory effects of immune reactions upon the growth of untransplanted tumors. Cancer Res 1994; 54: 908-14.
39. Stewart THM, Tsai SCJ. Review. The possible role of stromal cell stimulation in worseing the prognosis of a subset of patients with breast cancer. Clin Exp Metastasis 1993; 11: 295-305.
40. Champion HR, Wallace IWJ, Prescott RJ. Histology in breast cancer prognosis. Br J Cancer 1972; 26: 129-38.
41. Fisher B, Saffer EA, Fisher ER. Studies concerning the regional lymph nodes in cancers VII. Thymidine uptake by celts from nodes of breast cancer patients relative to axillary location and histopathologic discrimination. Cancer 1974; 33: 271-9.
42. Meyer JS and Hixon B. Advanced stage and early relapse of breast carcinomas associated with high thymidine labelling indices. Cancer Res; 1979; 39: 4042-7.
43. Fisher ER, Kotwal N, Hermann C, Fisher B. Types of tumor lymphoid response and sinus histiocytosis. Arch of Path and Lab Medicine 1983; 107: 222-7.
44. Parkes H, Collis C, Baildam A, et al.: in situ hybridization and S. mapping show that the presence of plasma cells is associated with poor prognosis in breast cancer. Br J Cancer 1988; 58: 715-22.
45. Rosen PP, Groshen S. Factors influencing survival and prognosis in early breast carcinoma: assessment of 644 patients with median follow-up of 18 years. Surg Clin NA 1990; 70: 937-962.
46. Kurtz JM, Jacquemeier J, Almaric R, et al. Why are local recurrences after breast-conserving therapy more frequent in younger patients? J Clin Oncology 1990; 8: 591-8.
47. Pupa SM, Menard S, Andreola S, et al. Prognostic significance for C-erb B-2 oncoprotein overexpression in breast carcinoma patients and its immunological role. Proc Amer Ass Cancer Res 1992; 31: 312.
48. Tang R, Kacinski B, Validire P, et al. Oncogene amplification correlates with dense lymphocytic infiltration in human breast cancers: A role for hematopoetic growth factor release by tumor cells? J Cell Biochem 1990; 44: 189-98.
49. Press MF, Pike MC, Chazin VR, et al. Her-2/neu expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993; 53: 4960-70.
50. Wanebo HJ, Rosen PP, Thaler T, et al. immunobiology of operable breast cancer: an assessment of biologic risk by immunoparameters. Ann Surgery 1976; 184: 258-67.
51. Pouillart P, Palangie T, Jouve M, et al. Cancer inflammatoire du sein traité par une association de chimio-thérapie et d'irradiation, résultat d'un essai randomisé étudiant le rôle d'une immunothérapie par le BCG. Bull Cancer 1981; 68: 171-86.
52. Mourali N, Levine PH, Tabanne F, et al. Rapidly progres-sing breast cancer (poussée évolutive) in Tunisia: studies on delayed hypersensitivity. Int J Cancer 1978; 22: 1-3.
53. Levine PH, Mourali N, Tabanne F, et al. Studies on the role of cellular immunity and genetics in the etiology of rapidly progressing brest cancer in Tunisia. Int J Cancer 1981; 27: 611-5.
54. Meyer JS, Hixon B. Advanced stage and early relapse of breast carcinomas associated with high thymidine labelling indices. Cancer Res 1979, 39: 4042-7.
55. Cannon GB, Dean JH, Herberman RB. Lymphoproliferative responses to alloantigen by postoperative patients with stage I lung and breast cancer and their application to prognosis. In: Dean JH, Padarathsingh M, (eds). Biological relevance of immune suppression. New York: Van Nostrand Reinhold 1981; 98-118.
56. Parkes H, Collis C, Baildam A, et al. In situ hybridisation and SI mapping show that the presence of infiltrating plasma cells is associated with poor prognosis in breast cancer. Br J Cancer 1988; 58: 715-22.
57. Grace JT, Dao TL. Etiology of inflammatory reactions in breast cancer. Surg Forum 1958; 9: 611-4.
58. Guerin M, Gabillot M, Mathieu MC et al. Structure and expression of C-erb B-2 and EGF receptor genes in inflammatory and noninflammatory breast cancer; prognostic significance. Int J Cancer 1989; 43: 201-8.
59. Pupa SM, Menard S, Andreola S, Colnaghi MI. Antibody response against the c-erb B-2 oncoprotein in breast carcinoma patients. Cancer Res 1993; 53: 5864-6.
60. Disis ML, Calenoff E, McLaughlin G, et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 1994; 54: 16-20.
61. Ethier SP, Kokeny KE, Ridings JW, Dilts CA. ErbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line. Cancer Res 1996; 56: 899-907.
62. Stancovski L, Hurwitz E, Leitner O, et al. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB-2 receptor on tumor growth. Proc Natl Acad Sci USA 1991; 88: 8691-5.
63. Rubbert A, Manger B, Lang N, et al. Functional characterization of tumor-infiltrating lymphocytes, lymph-node lymphocytes and peripheral blood lymphocytes from patients with breast cancer. Int J Cancer 1991; 49: 25-31.
64. Schwartzentruber DJ, Solomon D, Rosenberg SA, Topalian SL Characterization of lymphocytes infiitrating human breast cancer: specific immune reactivity detected by measuring cytokine secretion. J Immunotherapy 1992; 12: 1-12.
65. Vitolo D, Zerbe T, Kanbour A, et al. Expression of mRNA for cytokines in tumor-infiltrating mononuclear cells in ovarian adenocarcinoma and invasive breast cancer. Int J Cancer 1992; 51 : 573-80.
66. Mantovani A, Bottazzi B, Colotta F, et al. The origin and function of tumor-associated marcrophages. Immunology Today 1992; 13: 265-270.
67. Michiel DF, Oppenheim JJ. Cytokines as positive and negative regulators of tumor promotion and progression. Cancer Biology 1992; 3: 3-15.
68. Peoples GE, Blotnick S, Takahashi K, et al. T lymphocytes that infiltrate tumors and atherosclerotic plaques produce heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor: a potential pathologic role. Proc Natl Acad Sci USA 1995; 92: 6547-51.
69. Freeman MR, Schneck FX, Gagnon ML, et al. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancer express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res 1995; 55: 4140-5.
70. Lu Q, Brodie A Stimulation of the growth of MCF-7 and MDA-MB-468 breast cancer cells by vascular endothelial growth factor. Proc Am Ass Cancer Res 1996; 37: 220.
71. Tsai SJ, Miller F, Wei WZ, Heppner GH. Tumor necrosis factor (TNF) modulates growth of normal and neoplastic murine mammary cells. Proc Am Ass Cancer Res 1992; 33: 269.
72. Heppner GH, Miller BE. Enhanced tumor progression following TNFα or interferon treatment of mice bearing preneoplastic lesions. Proc Am Ass Cancer Res 1996; 37: 157.
73. Fräter-Schröder M, Risau W, Hallmann R, et al. Tumor necrosis factor type α, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci USA 1987; 84: 5277-81.
74. Leibovich SJ, Polverini PJ, Shepard HM, et al. Macrophage-induced angiogenesis is mediated by tumor necrosis factor α. Nature 1987; 329: 630-2.
75. Weidner N, Sample JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis correlation in invasive breast carcinoma. N Engl J Med 1991: 324: 1-8.
76. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1995; 1: 27-31.
77. Sehgal PB, Tamm I. Interleukin-6 enhances motility of breast carcinoma cells. In: Goldberg I.D. (ed). Cell motility factors. Basel: Birkhäuser Verlag 1991; 178-93.
78. Basolo F, Calvo S, Fiore L, et al. Growth-stimulating activity of interleukin-6 on human mammary epithelial cells transfected with the int-2 gene. Cancer Res 1993; 53: 2957-60.
79. Scholl SM, Crocker P, Tang R, et al. Is colony-stimulating factor-1 a key mediator of breast cancer invasion and metastasis. Molecular Carcinogenesis 1993; 7: 207-11.
80. Fidler IJ, Brodey RS, Beck-Nielsen S. In vitro immune stimulation - inhibition to spontaneous canine tumors of various histoogical type. J Immunol 1974; 112: 1051-60.
81. Ögmundsdottir HM, Petersdottir I, Gudmunsdottir. Interactions between the immune system and breast cancer. Acta Oncologica 1995; 34: 647-50.
82. Petersen OW, van Deurs B. Preservation of defined phenotypic traits in short-term cultured human breast carcinoma derived epithelial cells. Cancer Res 1987; 47: 850-66.
83. Stewart THM, Retsky MW, Tsai SCJ, Verma S. Dose response in the treatment of breast cancer. Lancet 1994; 343: 402-4.
84. Zielinski CC, Müller C, Kubista E, et al. Effects of adjuvant chemotherapy on specific and nonspecific immune mechanisms. Acta Med Austr 1990; 17: 11-4.
85. Weite K, Cioban̄u N, Moore MAS, et al. Defective interleukin 2 production in patients after bone marrow transplantation and in vitro restoration of defective T lympocyte proliferation by highly purified interleukin 2. Blood 1984; 64: 380-5.
86. Olsen GA, Gockerman JP, Basr RC, et al. Altered immunologic reconstitution after standard-dose chemotherapy or high-dose chemotherapy with autologous bone marrow support. Transplantation 1988; 46: 57-60.
87. Stewart THM. Post-mastectomy radiotherapy: more than a local matter. Lancet 1994; 344: 351.
88. Robinson E, Rubin D, Mekori T, et al. In vivo modulation of natural killer cell activity by tamoxifen in patients with bilateral primary breast cancer. Cancer Immunol Immunother 1993; 37: 209-12.
89. Bittner JJ. Some possible effects of nursing on the mammmary gland tumor incidence in mice. Science 1936; 84: 162.
90. Wei WZ, Gill RF, Wang H. Mouse mammary tumor virus associated antigens and superantigens-immuno-molecular correlates of neoplastic pro-gression. Semin Cancer Biology 1993; 4: 205-13.
91. Wang Y, Holland JF, Bleiweiss U, et at. Detection of mammary tumor virus ENV gene-like sequences in human breast cancer. Cancer Res 1995; 55: 5173-5179.
92. Evans I. Lancet conference. The challange of breast cancer. Lancet 1994; 343: 1085-6.
93. Stewart THM, Tsai SCJ, Grayson H, et al. Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet 1995; 346: 796-8.
94. Pross HF, Sterns E, MacGillis DR. Natural killer cell activity in women at «high risk» for breast cancer, with and without benign breast syndrome. Int J Cancer 1984; 34: 303-8.
95. Cannon GB, Barsky SH, Alford TC, et al. Cell-mediated immunity to mouse mammary tumor virus antigens by patients with hyperplastic benign breast disease. J Natl Cancer Inst 1982; 68: 935-43.
96. Wei WZ, Miller FR, Balzor BA, et al. Opposing effects of cryostat sections of preneoplastic and neoplastic mouse mammary lesions on in-vitro migration of periotoneal exudate cells. J Immunol 1979; 122: 2059-67.